<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70140">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02192684</url>
  </required_header>
  <id_info>
    <org_study_id>5U01HL108647-04</org_study_id>
    <nct_id>NCT02192684</nct_id>
  </id_info>
  <brief_title>Obesity, Sleep Apnea, and Insulin Resistance</brief_title>
  <official_title>Interfacing Adiposity, Sleep Apnea, and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) and type 2 diabetes confer increasing economic, social, and
      public health burdens in the United States. That these diseases appear to co-exist and
      together increase one's risk of cardiovascular disease renders investigation into their
      shared pathophysiology even more urgent. Investigators will assess prevalence of insulin
      resistance, a precursor to diabetes, among overweight patients with OSA. Among those at
      highest risk of diabetes, investigators will randomize participants to pioglitazone or
      placebo to see the efficacy of the intervention on improving OSA, insulin resistance, and/or
      insulin secretion. In a separate intervention, investigators will evaluate the
      cardiometabolic benefits of continuous positive airway pressure (CPAP) for 12 weeks in
      patients with OSA. Investigators will also study subjects from the community without known
      sleep apnea, and assess whether insulin-resistant individuals are at risk for sleep apnea
      using clinical screening questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in apnea-hypopnea index (AHI) outcome measure in response to pioglitazone or placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the effects of pioglitazone versus placebo on AHI in patients with OSA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity outcome measure in response to pioglitazone or placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in insulin sensitivity in patients with OSA randomized to pioglitazone or placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in insulin sensitivity outcome measure in response to CPAP</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the effect of CPAP on insulin resistance and cardiometabolic risk factors in patients with OSA.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pioglitazone 45 mg, oral, daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, one pill daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>45 mg daily Insulin sensitizing</description>
    <arm_group_label>pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Compare with pioglitazone</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Individuals

          -  Age 30-70 years old

          -  BMI- 25-40 kg/m2

          -  Must meet criteria for obstructive sleep apnea by overnight in-laboratory
             polysomnography

        Exclusion Criteria:

          -  Any significant co-morbidities, such as diabetes, active heart, kidney, liver
             diseases, or active or history of bladder cancer.

          -  Must not have previously received treatment for OSA, including CPAP.

          -  Must not be receiving any medications intended for weight loss, or those known to
             influence insulin sensitivity.

          -  Pregnancy/lactation is also an exclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 16, 2014</lastchanged_date>
  <firstreceived_date>July 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Gerald M Reaven</investigator_full_name>
    <investigator_title>Professor Emeritus</investigator_title>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>positive airway pressure therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
